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Background: By increasing the intracellular prooxidant burden, gamma-glutamyltransferase 
(GGT) may accelerate atherosclerotic vascular disease. That noxious influence may be reflected 
by circulating enzyme levels, a correlate of cardiovascular risk factors, and a predictor of inci-
dent events. To evaluate this hypothesis, we tested the association between circulating GGT and 
common carotid intima-media thickness (CIMT), a surrogate index of systemic atherosclerotic 
involvement, in a large and well-characterized group of patients at risk of cardiovascular disease 
(CVD).
Patients: This study analyzed 548 patients with hypertension and/or diabetes and a widely 
prevalent history of CVD. Subjects with known hepatic disease and abnormal GGT values 
were excluded.
Methods: CIMT (B-mode ultrasonography) values were the mean of four far-wall measurements 
at both common carotids. Metabolic syndrome (MetS) was diagnosed according to National 
Cholesterol Education Program-Adult Treatment Panel III criteria. Due to inherent sex-related 
differences in GGT levels, the data were analyzed separately in males and females in samples 
dichotomized by the median.
Results: The age-adjusted CIMT values did not differ by GGT levels in males or females. In 
contrast, the carotid wall was consistently thicker in patients with a history of CVD and MetS 
independent of age and concurrent GGT values. In both sexes, GGT was associated with key 
components of the MetS such as triglycerides, fasting plasma glucose, and body mass index.
Conclusion: The data collected in this mixed group of hypertensive and/or diabetic patients 
with widely prevalent history of CVD do not support the concept of a direct pathophysiological 
link between GGT levels within reference limits and atherosclerotic involvement.
Keywords: gamma-glutamyltransferase, carotid intima-media thickness, atherosclerosis, 
metabolic syndrome
Introduction
Consistent evidence associates increased circulating serum gamma-glutamyltransferase 
(GGT), a parameter conventionally used for diagnosing hepatobiliary diseases and 
alcohol abuse,1 with incident cardiovascular disease (CVD)2 and major proathero-
genic risk factors.3 For this reason, GGT determination has been added to the array 
of b  iomarkers useful for stratifying cardiometabolic risk.4 Furthermore, the enzyme’s 
active involvement in the atherogenic process was hypothesized on the basis of its 
potential to increase the intracellular prooxidant burden through the iron-reducing 
properties of cysteinylglycine moieties generated during GGT-catalyzed glutathione 
hydrolysis.5 The identification of prooxidant GGT activity in atheromatous plaques of 
carotid and coronary arteries6 adds to the need for further clinical evaluation.
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Since the first demonstration of its close correlation with 
directly measured arterial wall thickness, carotid intima-
media thickness (CIMT) determination7 has become an 
easily obtained and noninvasive standard surrogate measure 
of systemic atherosclerosis and a prognostic and therapeutic 
end-point in epidemiological and pharmacological trials.8 
Therefore, ultrasound-derived CIMT offers a way to assess 
the relationship between GGT levels and atherosclerotic 
vascular disease. This rarely addressed issue was evaluated 
in this retrospective cross-sectional analysis of a large 
and well-characterized sample of patients screened at our 
institution.
Materials and methods
Patients
This study examined 548 consecutive Caucasian subjects 
who were referred to our department between January 2006 
and June 2010 for hypertension and/or diabetes. Table 1 
provides clinical and demographic characteristics of the 
sample.   Subjects with history of liver disease, self-reported 
alcohol abuse, history of hepatitis B or C, anticonvulsants, 
and microsomal enzyme-inducing drugs active on hepatic 
GGT release1 were excluded. Only patients with GGT levels 
within the reference values of our laboratory (,60 e 40 U/L 
for males and females, respectively) were included in the 
analysis. Statin and antihypertensive (mostly angiotensin-
converting enzyme inhibitors (ACEIs), angiotensin-receptor 
blockers (ARBs), and calcium channel blockers) treatment at 
the time of the visit was retrieved from the records. Table 1 
presents the relative percentages.
Carotid-scanning protocol
The patients were screened while in supine position with the 
head and neck gently rotated 45 degrees from the side where 
the scanning was performed. The examination started by visu-
alizing the longitudinal image of the midportion of the com-
mon carotid arteries in the supraclavicular region by moving 
and rotating the transducer until the sonographer demonstrated 
and marked the bifurcation with the cursor. Next, the sonogra-
pher focused on the interfaces required for the measurements 
of the arterial wall thickness of the common carotid artery 
(CCA) segment within 40 mm proximal to the carotid bulb. 
Patients with arteries in which the references were unidentifi-
able, tortuous, or calcified were excluded. All measurements 
were made with the image at the maximum depth of focus. The 
operator set up the gains and image pre- and post-processing 
options for every patient and for each artery to obtain the best 
possible image. Measurements of the distance from the leading 
edge of the first echogenic luminal, bright line to the leading 
edge of the second echogenic line were taken manually from 
frozen images as indicated by Pignoli7 in order to express 
the distances in mm. Scanning and measurements were 
obtained by a Philips ie33® instrument (Philips, Eindhoven, 
The Netherlands) equipped with a linear 7.5 MHz probe (axial 
resolution: 0.1 mm) and by the same observer (MN, within-
observer variability: 5.3%, the average variation coefficient 
of 20 triplicate measurements in control subjects).
Biochemistry
GGT was measured colorimetrically by the nitroanilide 
method on a Cobas Mira Plus (Roche, Mannheim, Germany) 
chemistry instrument. Alanine aminotransferase (ALT), 
fasting plasma glucose (FPG), total cholesterol (CHOL), low-
density lipoprotein-cholesterol (LDL-CHOL), high-density 
lipoprotein-cholesterol (HDL-CHOL), and triglycerides were 
assessed by automated standard enzymatic and colorimetric 
methods. All the samples were processed in the same labora-
tory, and quality control was ensured by the regional branch 
of the National Health System (Regione Toscana, Controllo 
di Qualità in Medicina di Laboratorio9).
The systolic (S) and diastolic (phase V Korotkoff) blood 
  pressure (BP) values refer to sphygmomanometric measure-
ments taken in sitting position at the time of CIMT determination. 
Table 1 Demographic and clinical characteristics by sex
Variables Females 
n = 217
Males 
n = 331
P-value
CIMT (mm) 0.80 ± 0.19 0.86 ± 0.20 ,0.001
GGT (U/L) 15 (9) 27 (20) ,0.001
ALT (U/L) 17 (7) 22 (13) ,0.001
Triglycerides (mg/dL) 93 (57) 118 (77) ,0.001
FPG (mg/dL) 90 (16) 95 (18) ,0.001
BMI (Kg/m2) 25.6 ± 4.7 26.8 ± 3.5 ,0.001
Diabetes 10% 22% ,0.001
Active smokers 12% 25% ,0.001
History of CVD 19% 40% ,0.001
Statins 54% 67% ,0.01
Antihypertensive Rx 51% 70% ,0.001
Total-CHOL (mg/dL) 216 ± 38 195 ± 38 ,0.001
LDL-CHOL (mg/dL) 140 ± 36 131 ± 37 ,0.01
HDL-CHOL (mg/dL) 67 ± 15 52 ± 14 ,0.001
Age (years) 59 ± 14 60 ± 13 NS
SBP (mmHg) 133 ± 18 133 ± 16 NS
Hypertension 75% 80% NS
Note: Means ± SD, medians (interquartile range) and percentages.
Abbreviations: ALT, alanine transferase; BMI, body mass index; CVD, cardiovascular 
disease;  FPG,  fasting  plasma  glucose;  GGT,  gamma-glutamyltransferase; 
HDL-CHOL,  high-density  lipoprotein-cholesterol;  LDL-CHOL,  low-density 
lipoprotein-cholesterol;  NS,  nonsignificant;  SBP,  systolic  blood  pressure;   
SD, standard deviation.
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Body weight was measured to the nearest 0.1 kg on a scale 
with an attached height measurement device.
Definitions
Cardiovascular disease (CVD) includes coronary heart 
disease (previous myocardial infarction, unstable and stable 
angina, coronary artery bypass graft, or angioplasty), periph-
eral arterial disease (previous lower limb surgery, angioplasty, 
or current claudication confirmed by echo-Doppler stud-
ies, angiograms, or others), and carotid disease (previous 
endarterectomy or carotid stenosis .50% at echo-Doppler 
imaging) (Table 2). Diabetes and hypertension were either 
diagnosed based on ongoing treatment or by the presence of 
fasting plasma glucose .125 mg/dL and BP .130/85 respec-
tively. Metabolic syndrome (MetS) was defined according to 
National Cholesterol Education Program-Adult Treatment 
Panel III (NCEP-ATP III) criteria10 in the presence of at least 
three of the following criteria: antihypertensive treatment 
or BP .130/85 mmHg, triglycerides $150 mg/dL, HDL-C 
,40 mg/dL in males and ,50 mg/dL in females, glucose-
lowering treatment, or FPG .110 mg/dL, abdominal obesity. 
The thresholds for abdominal obesity were BMI $29.5 kg/m2 
and $27.2 kg/m2 in men and women, respectively since those 
values corresponded to 102 cm and 88 cm of waist circumfer-
ence in men and women, respectively, in a regression of BMI 
on the waist as validated previously.11 Smokers were either 
categorized as current smokers independent of the number 
of cigarettes they had per day or as never/previous smokers, 
meaning tobacco-free for at least 6 months.
Data processing
The data were analyzed by sex-specific median GGT 
values (cutoffs: 15 U/L and 27 U/L for females and males, 
  respectively). CIMT was the average of the four values mea-
sured bilaterally approximately 1 cm from the other at the 
far wall of the CCA, provided that these points were free of 
plaque. Plaques (a local thickening exceeding 1.4 mm and pro-
truding into the lumen) were excluded from the   measurements. 
BMI was calculated as weight/height2 (Kg/m2). For the sake 
of clarity, only the SBP values were reported since diastolic 
BP did not vary across comparisons.
Statistics
Differences in continuous and categorical variables were 
assessed by one-way analysis of variance and chi-square 
statistics, respectively, and were adjusted for age by analysis 
of covariance and logistic regression. Unless otherwise speci-
fied, descriptive statistics were mean ± standard deviation or 
median (interquartile range) for skewed data and percentages 
for categorical variables. The limit for statistical significance 
was P , 0.05.
Results
Clinical and demographic characteristics 
by gender
CIMT, GGT ALT, triglycerides, FPG, BMI were higher and 
diabetes, active smoking, history of CVD, and pharmacological 
treatment more frequent in males than females whereas total 
and fractionated CHOL showed opposite trends. Age, SBP, and 
history of hypertension did not differ by gender (Table 1).
Clinical and demographic characteristics 
by GGT status in males and females
In contrast to the homogeneous distribution of such param-
eters in men, thicker carotid walls (Figure 1), higher SBP, and 
more frequent hypertension and statin treatment distinguished 
women with above from those below median GGT levels 
(Table 3). However, differences in CIMT (Age-corrected 
means [95% confidence interval (CI)]: 0.80 [0.77–0.83] 
versus 0.79 [0.76–0.81] mm) and in other parameters (data 
not shown) were abolished by accounting for the older age of 
the female subgroup (Table 3). In both sexes, above-median 
GGT levels were associated with higher ALT, triglycerides, 
FPG, and BMI (Table 3).
Table 2 Distribution (absolute numbers and percentages) by type 
of vascular disease (n = 174) in descending order of frequency
Type of vascular disease n = 174 %
Multivessel disease 71 40
Coronary heart disease 50 29
Carotid artery disease 43 25
Peripheral vascular disease 10 6
Note: Multivessel disease indicates the coexistence in the same patient of two or 
more of the listed vascular diseases.
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Figure  1  Box-and-whisker  plots  of  carotid  intima-media  thickness  (CIMT)  by 
above- and below-median gamma-glutamyltransferase (GGT) levels in females (left 
panel) and males (right panel).
Notes: The statistical difference in women was abolished when age difference was 
taken into account. The central box encloses the middle 50% of the data; the horizontal 
line inside the box represents the median, and the mean is plotted as a cross. Vertical 
lines (whiskers) extend from each end of the box and cover four interquartile ranges.
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The flat behavior of CIMT by GGT levels diverged quite 
sharply from the carotid thickening shown by patients with a 
history of CVD as compared with those without, a statistically 
significant (P , 0.001) pattern unaffected by the adjustment 
for age (Figure 2). Circulating GGT levels were comparable 
in patients with a history of CVD and not, either females   
(17 [9] versus 14 [8] U/L, n = 41 versus 176 respectively, 
NS) or males (26 [20] versus 28 [19] U/L, n = 133 versus 
198 respectively, NS).
Clinical and demographic characteristics 
by MetS status
Besides the expected liver enzyme elevations4 and definition-
related10 modifications of the metabolic and pressor profile 
(Table 4), CIMT was higher in patients with MetS (Figure 3) 
Table 3 Demographic and clinical characteristics by above- and below-median sex-specific GGT levels
Variables Females 
n = 217
Males 
n = 331
,15 U/L 
n = 107
$15 U/L 
n = 112
P-level ,27 U/L 
n = 164
$27 U/L 
n = 167
P-level
GGT (U/L) 11 (3) 20 (8) – 19 (9) 39 (14) –
Age (years) 55 ± 14 64 ± 12 ,0.001 61 ± 15 59 ± 12 NS
SBP (mmHg) 128 ± 18 138 ± 17 ,0.001 132 ± 15 135 ± 15 NS
Hypertension 64% 87% ,0.001 79% 87% NS
Statins 40% 68% ,0.001 63% 71% NS
Antihypertensive Rx 40% 63% ,0.01 65% 74% NS
ALT (U/L) 15 (6) 18 (7) ,0.001 19 (9) 25 (15) ,0.001
Triglycerides (mg/dL) 81 (42) 108 (67) ,0.001 102 (71) 126 (74) ,0.01
FPG (mg/dL) 86 (13) 95 (16) ,0.001 94 (17) 97 (21) ,0.01
BMI (Kg/m2) 24.8 ± 4.5 26.3 ± 4.4 ,0.05 26.0 ± 2.9 27.5 ± 3.6 ,0.001
Total-CHOL (mg/dL) 209 ± 38 223 ± 37 ,0.01 190 ± 39 200 ± 35 ,0.05
LDL-CHOL (mg/dL) 133 ± 38 146 ± 35 ,0.01 127 ± 37 136 ± 35 ,0.05
HDL-CHOL (mg/dL) 68 ± 15 66 ± 15 NS 54 ± 15 51 ± 13 NS
Active smokers 12% 12% NS 22% 25% NS
History of CVD 16% 22% NS 41% 39% NS
Diabetes 7% 13% NS 19% 25% NS
Note: Means ± SD, medians (interquartile range) and percentages.
Abbreviations: ALT, alanine transferase; BMI, body mass index; CVD, cardiovascular disease; FPG, fasting plasma glucose; GGT, gamma-glutamyltransferase; HDL-CHOL, 
high-density lipoprotein-cholesterol; LDL-CHOL, low-density lipoprotein-cholesterol; NS, nonsignificant; SBP, systolic blood pressure; SD, standard deviation.
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Figure  2  Box-and-whisker  plots  of  CIMT  by  history  of  cardiovascular  disease 
(CVD) in females (left panel) and males (right panel).
Notes: The central box encloses the middle 50% of the data; the horizontal line 
inside the box represents the median, and the mean is plotted as a cross. Vertical lines 
(whiskers) extend from each end of the box and cover four interquartile ranges.
and was unchanged after adjusting for GGT levels (GGT-
corrected means [95% CI]: 0.82 [0.80–0.84] versus 0.88 
[0.86–0.92] mm, P , 0.01).
Discussion
The lack of relationship between GGT 
and CIMT
Our cross-sectional evaluation of a large and rather 
heterogeneous group of hypertensive and/or diabetic 
patients widely affected by CVD shows a lack of association 
Table 4 Demographic and clinical characteristics by MetS status
Variables No MetS 
n = 439
MetS 
n = 109
P-level
GGT (U/L) 19 (16) 27 (15 ,0.001
ALT (U/L) 19 (9) 24 (18) ,0.001
Triglycerides (mg/dL) 96 (51) 186 (68) ,0.001
FPG (mg/dL) 94 (15) 115 (29) ,0.001
HDL-CHOL (mg/dL) 61 ± 15 45 ± 15 ,0.001
BMI (kg/m2) 25.4 ± 3.6 29.6 ± 4.1 ,0.001
SBP (mmHg) 132 ± 17 139 ± 16 ,0.001
Diabetes 10% 46% ,0.001
Hypertension 65% 90% ,0.001
M/F 42%/58% 32%/68% NS
Age (years) 60 ± 14 61 ± 12 NS
Note: Means ± SD, medians (interquartile range) and percentage.
Abbreviations:  ALT,  alanine  transferase;  BMI,  body  mass  index;  FPG, 
fasting  plasma  glucose;  GGT,  gamma-glutamyltransferase;  HDL-CHOL,  high-
density  lipoprotein-cholesterol;  MetS,  metabolic  syndrome;  NS,  nonsignificant;   
SBP, systolic blood pressure; SD, standard deviation.
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between circulating GGT levels and CIMT, a surrogate 
measure of systemic atherosclerosis.8 This negative result 
was immediately evident in men and emerged quite clearly 
in women after accounting for the older age of those with 
higher GGT. That demographic influence was consistent 
with previous reports1 of trends toward declining values 
in elderly males whose large representation in our sample 
may explain why age and GGT showed a different associa-
tion profile between sexes. One might also ask whether the 
effect of statins on liver enzymes12 might have contributed 
to the divergent pattern, but this is unlikely since statin 
treatment did not differ by GGT levels in males, and was 
appropriately more frequent in older females with higher 
GGT levels. The strength of these findings is augmented 
when contrasted with the carotid thickening that character-
ized patients with a history of CVD, a reassuring piece of 
evidence in agreement with the concept of carotid imaging 
as an indicator of the atherosclerotic burden across different 
vascular beds.8
Our results are inconsistent with the active contribution 
of GGT in the initiation and progression of atherosclerotic 
vascular disease, at least to the extent reflected by carotid 
imaging. This issue has been addressed by a few studies 
biased by low statistical strength of the reported correlations, 
limited sample size, unbalanced male-to-female ratios and, 
most importantly, missing adjustment for sex and age.13–15 
This latter limitation is of particular relevance when con-
sidering the confounding effect of demographic variables 
on CIMT in our study. This is in agreement with Volzke 
et al’s study on a large sample of patients with nonalcoholic 
fatty liver disease (NAFLD)16 in which anatomic alterations 
ranging from mere liver steatosis to steatohepatitis coexisted 
with elevated GGT and related metabolic abnormalities.17,18 
Our conclusions are further supported by negative results 
reported in several series of patients with NAFLD,19–22 a 
condition that affected also an   undefined but large portion of 
our patients, particularly those with higher ALT, a measure of 
hepatic fat accumulation.23 It must be recognized, however, 
that the issue of the NAFLD as a marker of more advanced 
carotid atherosclerosis is controversial24 and our data can-
not provide any evidence in favor or against that possibility 
since we have no information about the liver status of our 
patients.
GGT, CIMT, and MetS
The clustering of elevated GGT and ALT levels with higher 
BMI, FPG, triglycerides, and BP by the NCEP-ATP III defini-
tion of MetS10 agrees with the findings of previous epidemio-
logical observations25 linking the liver, the primary source of 
those enzymes,17,18 to a biological phenotype at high risk of 
CVD and diabetes.26 In concordance with previous studies27,28 
based on similar diagnostic criteria,10 we found evidence 
of more advanced subclinical atherosclerosis in patients 
with MetS. More importantly, in light of our specific aims, 
the persistence of that difference after accounting for GGT 
implies an overcoming influence of metabolic abnormalities 
on atherosclerotic progression, which is fully concordant 
with other studies.29,30
Limitations of the study
The conclusions of our study must be considered in the 
context of some important limitations. First and more impor-
tantly, cross-sectional studies such as this one may establish 
associations or lack thereof, but are weak tools for assessing 
mechanistic links. Second, the common carotid arteries might 
be less prone to atherosclerosis than the bulb or the internal 
carotid arteries31 and the impact of cardiovascular risk fac-
tors may differ across carotid segments.32 Moreover, carotid 
plaques, which were not considered in our study, could relate 
to GGT more tightly than CIMT16 as a reflection of different 
biological and genetic determinants of the atherosclerotic 
process.33 Third, the pervasive use of statins as well as ACEIs 
and ARBs – a group of drugs endowed with pleiotropic 
anti-inflammatory and antioxidant properties34,35 – may 
have obscured associations discernible in untreated condi-
tions. That source of confounding is impossible, however, 
to be circumvented in retrospective studies as ours. Fourth, 
circulating GGT includes several heterogeneous molecular 
fractions that are undifferentiated by routine assays of which 
only the b-fraction may be associated with cardiovascular 
risk factors and may penetrate the atherosclerotic plaque.36 
Fifth, the impact of GGT on CIMT may only be evident 
in patients with pathological GGT elevations that were 
excluded from our series to avoid confounding from liver 
disease other than NAFLD, given the absence of ultrasound 
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Figure  3  Box-and-whisker  plot  of  carotid  intima-media  thickness  (CIMT)  by 
National  Cholesterol  Education  Program-Adult  Treatment  Panel  III  defined 
metabolic syndrome (MetS) status.10
Notes: The central box encloses the middle 50% of the data; the horizontal line 
inside the box represents the median, and the mean is plotted as a cross. Vertical lines 
(whiskers) extend from each end of the box and cover four interquartile ranges.
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or biopsy verification. However, this possibility applies, by 
definition, to a minority of subjects.
In conclusion, higher GGT values bore no relationship to 
common carotid IMT, a surrogate measure of atherosclerotic 
vascular disease, in this large group of high-risk subjects. 
The data do not support the concept of a pathophysiological 
link between GGT levels within reference limits and athero-
sclerotic involvement although further studies are needed to 
evaluate this possibility.
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